Get started

Acquistions

$WIFI to be Acquired by Digital ColonyBoingo Wireless to be Acquired by Digital Colony Boingo Shareholders to Receive $14.00 per share in Cash Transaction Valued at Approximately $854 Million. Leading Digital Infrastructure Investment Firm, Digital Colony, Uniquely Positioned to Continue Investing in Boingo’s Diverse Network. Boingo to Become a Privately Held Company Upon Completion of Transaction. Digital Colony will acquire all the outstanding shares of Boingo common stock for $14.00 per share in cash through a merger, in a transaction valued at approximately $854 million, including the assumption of $199 million of Boingo’s net debt obligations. The acquisition price represents a 23% premium to Boingo’s closing price of $11.40 on February 26, 2021. expected to close in the second quarter of 2021. finance.yahoo.com
W
by AlenCiken
1
ICON to Acquire PRA Health Sciences, Creating a World LeaderICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research The combined business will be no. 1 or 2 in key clinical market segments and have formal strategic partnerships with a majority of the top 20 biopharma companies, providing a platform for growth and innovation. A cash and stock transaction valued at approximately $12 billion, with the per share merger consideration consisting of $80 in cash and 0.4125 shares of ICON stock. The consideration represents an approximately 30% premium to PRA’s closing price as of February 23rd, 2021. The transaction is anticipated to be highly accretive delivering double-digit accretion in the first full year and growing to 20%+ thereafter, driven by growth momentum, estimated annual run-rate cost synergies of $150 million, and the combined effective tax rate decreasing to 14%, both to be realised in approximately 4 years. finance.yahoo.com
P
by AlenCiken
Goodyear to Acquire $TCB Creating Stronger U.S.-Based LeaderGoodyear to Acquire Cooper, Creating Stronger U.S.-Based Leader in Global Tire Industry Strengthens Leadership Position in Global Tire Industry - Combines Two Complementary Brand Portfolios with a Comprehensive Offering Across the Value Spectrum - Provides Significant, Immediate and Long-Term Financial Benefits - Opportunity to Create Additional Value from Manufacturing and Distribution - Increases Scale to Support Investments in New Mobility and Fleet Solutions The transaction is expected to close in the second half of 2021. finance.yahoo.com
C
by AlenCiken
$PGR Expand Commercial Lines Products with Acquisition of $PTVCBProgressive Expands Commercial Lines Products with Acquisition of Protective Insurance Leader in Commercial Auto Insurance Seeks to Expand Capabilities Protective Shareholders to Receive $23.30 Per Share in Cash $PGR and $PTVCB today announced that they have entered into a definitive agreement under which Progressive has agreed to acquire all of the outstanding Class A and Class B common shares of Protective for $23.30 per share in cash, for a total transaction value of approximately $338 million. The acquisition is expected to close prior to the end of the third quarter of 2021. This move allows us to add products that will help us support larger fleets and brings expertise in workers’ compensation coverage for the transportation industry, which are new areas of business for us and can help us to meet the needs of our commercial customers. finance.yahoo.com
P
by AlenCiken
Acquisition of Quellis Biosciences Inc.+private placementCatabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc. Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema Concurrent with the acquisition of Quellis, Catabasis entered into a definitive agreement for the sale of Series X convertible preferred stock (the "Series X preferred stock") in a private placement to a group of institutional accredited investors. Catabasis expects to use the proceeds from the private placement primarily to enable the completion of IND-enabling studies, Phase 1a, and Phase 1b/2 clinical trials for the lead program QLS-215 in hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Catabasis expects to file an Investigational New Drug application for QLS-215 in the first half of 2022 and plans to initiate a Phase 1 clinical trial with initial results anticipated by the end of 2022. Subsequently, Catabasis expects to initiate a Phase 1b/2 trial in patients affected by HAE in 2023 with initial results anticipated by the end of 2023. About the Transactions finance.yahoo.com
C
by AlenCiken
Atlantic Power Agrees to be Acquired by I Squared CapitalAtlantic Power Agrees to be Acquired by I Squared Capital Common shareholders to receive US$3.03 per share in cash, representing a 48% premium to the 30-day volume weighted average price per common share on the NYSE - Convertible debentures to be converted to common shares, including a make whole premium; following conversion, debenture holders will receive US$3.03 per share in cash - Preferred shareholders and medium term noteholders to receive cash representing meaningful premiums to recent trading prices. The total enterprise value of the deal is approximately US$961 million (based on current foreign exchange rates) and the transaction was unanimously approved by Atlantic Power's board of directors. Atlantic Power's 6.00% Series E Convertible Unsecured Subordinated Debentures due January 31, 2025 will be converted into common shares of Atlantic Power immediately prior to the closing of the transaction based on the conversion ratio in effect at such time (including the "make whole premium shares" issuable under the terms of the trust indenture for the convertible debentures following a cash change of control). Holders of the convertible debentures will receive US$3.03 per common share held following the conversion of the convertible debentures, plus accrued and unpaid interest on the convertible debentures up to, but excluding, the closing date of the transaction. finance.yahoo.com
A
by AlenCiken
$BYOC Finishes Consolidation On Last Day of Tax Season.$BYOC Consolidated from .16 down to .05 on the final day of tax season moving quickly back over .06 on its way towards its third major leg up ahead of upcoming developments following the closing of its first acquisition, future uplistment to OTCQB (and NASDAQ way later down the road) and the possibility of 2-3 more acquisitions coming down the pipe this year. My LT target analysis is still firmly at a $2.00-$4.00 range by EOY into late spring of next year.
OTC:BYOCLong
by StockGuild